ETBIEastgate Biotech Corp.

About Eastgate Biotech Corp. (ETBI)

Eastgate Biotech Corp. (ETBI) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the Expert Market tier.

EastGate Biotech Corp. is a biotech company concentrating on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. We are developing a technology platform for enhanced drug delivery designed to improve compliance and increase health benefits to fit today's health-conscious lifestyles. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution based on a proprietary/Trade Secret composition for the treatment of Type 2 diabetes patients and Alzheimer's disease. We believe that our technology may also be applicable to the delivery of other active pharmaceutical ingredients. We may also develop other novel formulations of pharmaceutical and natural products. The company has identified several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions.

ETBI key facts

Ticker symbol

ETBI

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

US

Year of incorporation

1999

Estimated market cap

$4.76M (as of Apr 16, 2025)

Shares outstanding

1,057,857,377

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Jun 30, 2020)

Eastgate Biotech Corp. leadership

• Anna Gluskin — CEO
• Rose C. Perri — President
• William D. Abajian — COO
• Bill Abajian — COO
• Erwin Vahlsing, Jr. — Accountant
• Olga Naumova — Accountant

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with E